Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2019-06-12 Regulatory Filings
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Appointment of Joint Corporate Broker
Regulatory Filings Classification · 98% confidence The document is a short regulatory announcement (RNS) from the London Stock Exchange regarding the appointment of a new joint corporate broker for MaxCyte, Inc. It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a general corporate announcement distributed via the Regulatory News Service (RNS) that does not fall into a more specific category, it is classified as a Regulatory Filing.
2019-06-12 English
Save the Date: Capital Markets Day
Regulatory Filings Classification · 98% confidence The document is a short announcement (under 5,000 characters) issued via the Regulatory News Service (RNS) regarding an upcoming 'Capital Markets Day' event. It serves as an invitation and notification for analysts and investors rather than a full investor presentation or financial report. Since it does not fit into specific categories like 'Investor Presentation' (which would be the actual slide deck) or 'Earnings Release', and it is a general regulatory announcement, it is classified as a Regulatory Filing (RNS).
2019-05-29 English
Second Price Monitoring Extn
Regulatory Filings Classification · 100% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Second Price Monitoring Extension' for MaxCyte, Inc. It is a technical market announcement regarding trading volatility and auction extensions, which does not fit into specific categories like financial reports, dividends, or director dealings. As it is a standard regulatory market notice, it falls under the RNS category.
2019-05-08 English
Price Monitoring Extension
Regulatory Filings Classification · 100% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Price Monitoring Extension' for the security MaxCyte, Inc. It is a standard market operational notice rather than a financial report, management update, or corporate action. As it does not fit into specific categories like dividends, share issues, or earnings, it falls under the general regulatory announcement category.
2019-05-08 English
Final Results for Year Ended 31 December 2018
Earnings Release Classification · 100% confidence The document is an 'Earnings Release' (ER). It is titled 'MaxCyte Reports Final Results for Year Ended 31 December 2018', contains key financial highlights (Revenue, Gross margin, EBITDA), provides management commentary from the CEO, and includes details about an upcoming conference call. While it discusses annual results, it is structured as a press release (RNS Number: 8683W) rather than a full 10-K or Annual Report document. FY 2018
2019-04-24 English
Launch of ExPERTT Instrument Family
Regulatory Filings Classification · 98% confidence The document is a press release issued via the London Stock Exchange's RNS (Regulatory News Service) announcing the launch of a new product line (ExPERT instrument family) by MaxCyte, Inc. It does not constitute a formal financial report, proxy statement, or governance document. Since it is a general corporate announcement regarding product development and business operations, it falls under the 'Regulatory Filings' (RNS) category.
2019-04-08 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.